다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
한국임상약학회지 = Korean journal of clinical pharmacy, v.31 no.2, 2021년, pp.87 - 95
남재현 (한양대학교 약학대학) , 김채영 (한양대학교 약학대학) , 이유경 (한양대학교 약학대학) , 정다움 (한양대학교 약학대학) , 곽혜영 (한양대학교 서울병원) , 정지은 (한양대학교 약학대학)
AI-Helper
Background: Patients with chronic kidney disease (CKD) are at a high risk of stroke-related morbidity, mortality, and bleeding. However, the overall risk/benefit of anticoagulant therapy among patients with CKD remains unclear. Methods: The MEDLINE, EMBASE, and CENTRAL databases were comprehensively...
January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation 2019;140(2):e125-e51.
Pengo V, Banzato A, Bison E, et al. Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial. Lupus 2016;25(3):301-6.
Martin K, Beyer-Westendorf J, Davidson B, et al. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemost 2016;14(6):1308-13.
Chagnac A, Weinstein T, Korzets A, et al. Glomerular hemodynamics in severe obesity. Am J Physiol Renal Physiol 2000;278(5):F817-22.
Tobenkin A, Mohamoud M, Munoz M, et al. Direct oral anticoagulants and menorrhagia in premenopausal women: data from the food and drug administration adverse event reporting system and US drug utilization. Haemophilia 2017;23(Suppl 3):43.
Braekkan S, Van Der Graaf Y, Visseren F, et al. Obesity and risk of bleeding: the SMART study. J Thromb Haemost 2016;14(1):65-72.
Potpara TS, Ferro C, Lip GY, et al. Management of atrial fibrillation in patients with chronic kidney disease in clinical practice: a joint European Heart Rhythm Association (EHRA) and European Renal Association/European Dialysis and Transplantation Association (ERA/EDTA) physician-based survey. Europace 2020;22(3):496-505.
SAVAYSA(TM) oral tablets, edoxaban oral tablets. Daiichi, Sankyo. [Updated: 2015 January; cited 2020 July] Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf. Accessed March 1, 2021.
Sohal AS, Gangji AS, Crowther MA, et al. Uremic bleeding: pathophysiology and clinical risk factors. Thromb Res 2006; 118(3):417-22.
Ahuja T, Sessa K, Merchan C, et al. Oral factor Xa inhibitors versus warfarin for the treatment of venous thromboembolism in advanced chronic kidney disease. Adv Hematol 2021;2021:8870015.
Ghoshal S, Freedman BI. Mechanisms of stroke in patients with chronic kidney disease. Am J Nephrol 2019;50(4):229-39.
Wattanakit K, Cushman M, Stehman-Breen C, et al. Chronic kidney disease increases risk for venous thromboembolism. J Am Soc Nephrol 2008;19(1):135-40.
Wattanakit K, Cushrnan M. Chronic kidney disease increases risk for venous thromboembolism. Curr Opin Pulm Med 2009;15(5): 408-12.
Harel Z, Sholzberg M, Shah PS, et al. Comparisons between novel oral anticoagulants and vitamin K antagonists in patients with CKD. J Am Soc Nephrol 2014;25(3):431-42.
Amani A, Fellers CM, Eyebe A, et al. Safety and efficacy of apixaban use in peritoneal dialysis: A review of the literature. Journal of Pharmacy Technology 2021;37(3):147-51.
PRADAXA(R) oral capsules, dabigatran etexilate mesylate oral capsules. Boehringer Ingelheim. [Updated: April 2021; cited 2020 July]. Available from https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf. Accessed March 1, 2021.
XARELTO(R) oral tablets, rivaroxaban oral tablets. Janssen. [Updated: January 2021; cited 2020 July] Available from https://www.janssenlabels.com/package-insert/product-monograph/ prescribing-information/XARELTO-pi.pdf. Accessed March 1, 2021.
Parasrampuria DA, Truitt KE. Pharmacokinetics and pharmacodynamics of edoxaban, a non-vitamin K antagonist oral anticoagulant that inhibits clotting factor Xa. Clinical pharmacokinetics 2016;55(6):641-55.
Turner RM, Bird SM, Higgins JP. The impact of study size on metaanalyses: examination of underpowered studies in Cochrane reviews. PloS one 2013;8(3):e59202.
Furlan AD, Malmivaara A, Chou R, et al. 2015 updated method guideline for systematic reviews in the Cochrane Back and Neck Group. Spine (Phila Pa 1976) 2015;40(21):1660-73.
Herndon K, Guidry TJ, Wassell K, et al. Characterizing the safety profile of apixaban versus warfarin in moderate to severe chronic kidney disease at a veterans affairs hospital. Ann Pharmacother 2020;54(6):554-60.
Reed D, Palkimas S, Hockman R, et al. Safety and effectiveness of apixaban compared to warfarin in dialysis patients. Res Pract Thromb Haemost 2018;2(2):291-8.
Sarratt SC, Nesbit R, Moye R. Safety outcomes of apixaban compared with warfarin in patients with end-stage renal disease. Ann pharmacother 2017;51(6):445-50.
Schafer JH, Casey AL, Dupre KA, et al. Safety and efficacy of apixaban versus warfarin in patients with advanced chronic kidney disease. Ann Pharmacother 2018;52(11):1078-84.
Siontis KC, Zhang X, Eckard A, et al. Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States. Circulation 2018;138(15):1519-29.
Stanifer JW, Pokorney SD, Chertow GM, et al. Apixaban versus warfarin in patients with atrial fibrillation and advanced chronic kidney disease. Circulation 2020;141(17):1384-92.
Stanton BE, Barasch NS, Tellor KB. Comparison of the safety and effectiveness of apixaban versus warfarin in patients with severe renal impairment. Pharmacotherapy 2017;37(4):412-9.
Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) Eur Heart J 2020;41(4):543-603.
Lee CH, Lin TY, Chang SH, et al. Body mass index is an independent predictor of major bleeding in non-valvular atrial fibrillation patients taking dabigatran. Int J Cardiol 2017;228:771-8.
An SJ, Kim TJ, Yoon BW. Epidemiology, risk factors, and clinical features of intracerebral hemorrhage: an update. J Stroke 2017; 19(1):3-10.
Chokesuwattanaskul R, Thongprayoon C, Tanawuttiwat T, et al. Safety and efficacy of apixaban versus warfarin in patients with endstage renal disease: Meta-analysis. Pacing Clin Electrophysiol 2018;41(6):627-34.
Abdullah HM, Ullah W, Jafar MS, et al. Safety and efficacy of apixaban, rivaroxaban, and warfarin in end-stage renal disease with atrial fibrillation: A systematic review and meta-analysis. Cardiovasc Revasc Med 2020;doi:10.1016/j.carrev.2020.09.041.
Hanni C, Petrovitch E, Ali M, et al. Outcomes associated with apixaban vs warfarin in patients with renal dysfunction. Blood Advances 2020;4(11):2366-71.
Ionescu F, Cooper C, Petrescu I, et al. Safety of apixaban compared to warfarin in hemodialysis patients: Do antiplatelets make a difference? Eur J Haematol 2021;106(5):689-696.
Garlo K, Mavrakanas T, Wang W, et al. Stroke and Major Bleeding when Switching from Warfarin to Apixaban in Patients with Advanced Chronic Kidney Disease and Prevalent Atrial Fibrillation. Available from https://assets.researchsquare.com/files/rs-144190/v1/a4beec1a-e42a-4efe-a1fa-3ed7af424ae9.pdf. Accessed March 1, 2021.
Cho MS, Yun JE, Park JJ, et al. Pattern and impact of off-label underdosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation who are indicated for standard dosing. Am J Cardiol 2020;125(9):1332-8.
Labovitz AJ, Rose DZ, Fradley MG, et al. Early apixaban use following stroke in patients with atrial fibrillation: Results of the AREST trial. Stroke 2021;52(4):1164-71.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.